About UCSF Search UCSF UCSF Medical Center

Barry Taylor, PhD


Assistant Professor, Helen Diller Family Comprehensive Cancer Center; Division of Bioinformatics, Department of Epidemiology and Biostatistics; Division of Hematology/Oncology, Department of Medicine, UCSF


Phone: (415) 514-4924
Box 0128 , UCSF
San Francisco, CA 94143-0128

View on UCSF Profiles

Additional Websites


2006-09, Weill Medical College of Cornell University, PhD, Physiology, Biophysics, and Systems Biology
2004-06, University of Michigan. MS, Bioinformatics
1995-99, University of California, San Diego, BS

Professional Experience

  • 2012-present
    Faculty Member, California Institute for Quantitative Biosciences (QB3)
  • 2012-present
    Assistant Professor, Helen Diller Family Comprehensive Cancer Center and the Division of Bioinformatics, Department of Epidemiology and Biostatistics, UCSF
  • 2010-2012
    Visiting Scientist, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco (San Francisco, CA)
  • 2009-
    David H. Koch Fellow in Cancer Genomics, Memorial Sloan-Kettering Cancer Center (New York, NY)
  • 2006-09
    Graduate Student Research, Laboratory of Chris Sander, Computational Biology Center, Memorial Sloan-Kettering Cancer Center
  • 2004-06
    Graduate Student Research, Laboratory of Arul M. Chinnaiyan, Department of Pathology, University of Michigan Medical School
  • 1998-99
    Research Assistant, Laboratory of Edwin Hutchins, Department of Cognitive Science, University of California, San Diego

Honors & Awards

  • 2013
    UCSF Brain Tumor SPORE Career Development Research Award
  • 2011
    Young Investigator Award, Prostate Cancer Foundation (PCF)
  • 2009
    Young Investigator Award, Connective Tissue Oncology Society (CTOS) 15thAnnual Meeting [Shared with J. Barretina, Broad Institute]
  • 2008
    Second Place Award, Applied Biosystems SOLiDTM 3 System $10K GenomeGrant Program, Life Technologies, Inc.
  • 2008
    Geoffrey Beene Graduate Fellowship, The Geoffrey Beene Cancer ResearchCenter, Memorial Sloan-Kettering Cancer Center

Selected Publications

  1. Berger AH, Chen M, Morotti A, Janas JA, Niki M, Bronson RT, Taylor BS, Ladanyi M, Van Aelst L, Politi K, Varmus HE, Pandolfi PP. DOK2 Inhibits EGFR-Mutated Lung Adenocarcinoma. PLoS One. 2013; 8(11):e79526.
    View on PubMed
  2. Stumpf CR, Moreno MV, Olshen AB, Taylor BS, Ruggero D. The translational landscape of the Mammalian cell cycle. Mol Cell. 2013 Nov 21; 52(4):574-82.
    View on PubMed
  3. Olshen AB, Hsieh AC, Stumpf CR, Olshen RA, Ruggero D, Taylor BS. Assessing gene-level translational control from ribosome profiling. Bioinformatics. 2013 Dec 1; 29(23):2995-3002.
    View on PubMed
  4. Iyer G, Al-Ahmadie H, Schultz N, Hanrahan AJ, Ostrovnaya I, Balar AV, Kim PH, Lin O, Weinhold N, Sander C, Zabor EC, Janakiraman M, Garcia-Grossman IR, Heguy A, Viale A, Bochner BH, Reuter VE, Bajorin DF, Milowsky MI, Taylor BS, Solit DB. Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer. J Clin Oncol. 2013 Sep 1; 31(25):3133-40.
    View on PubMed
  5. Iyer G, Hanrahan AJ, Milowsky MI, Al-Ahmadie H, Scott SN, Janakiraman M, Pirun M, Sander C, Socci ND, Ostrovnaya I, Viale A, Heguy A, Peng L, Chan TA, Bochner B, Bajorin DF, Berger MF, Taylor BS, Solit DB. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012 Oct 12; 338(6104):221.
    View on PubMed
  6. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012 Jul 19; 487(7407):330-7.
    View on PubMed
  7. Crago AM, Socci ND, DeCarolis P, O'Connor R, Taylor BS, Qin LX, Antonescu CR, Singer S. Copy number losses define subgroups of dedifferentiated liposarcoma with poor prognosis and genomic instability. Clin Cancer Res. 2012 Mar 1; 18(5):1334-40.
    View on PubMed
  8. Hanrahan AJ, Schultz N, Westfal ML, Sakr RA, Giri DD, Scarperi S, Janakiraman M, Janikariman M, Olvera N, Stevens EV, She QB, Aghajanian C, King TA, Stanchina Ed, Spriggs DR, Heguy A, Taylor BS, Sander C, Rosen N, Levine DA, Solit DB. Genomic complexity and AKT dependence in serous ovarian cancer. Cancer Discov. 2012 Jan; 2(1):56-67.
    View on PubMed
  9. Taylor BS, DeCarolis PL, Angeles CV, Brenet F, Schultz N, Antonescu CR, Scandura JM, Sander C, Viale AJ, Socci ND, Singer S. Frequent alterations and epigenetic silencing of differentiation pathway genes in structurally rearranged liposarcomas. Cancer Discov. 2011 Dec; 1(7):587-97.
    View on PubMed
  10. Morris LG, Taylor BS, Bivona TG, Gong Y, Eng S, Brennan CW, Kaufman A, Kastenhuber ER, Banuchi VE, Singh B, Heguy A, Viale A, Mellinghoff IK, Huse J, Ganly I, Chan TA. Genomic dissection of the epidermal growth factor receptor (EGFR)/PI3K pathway reveals frequent deletion of the EGFR phosphatase PTPRS in head and neck cancers. Proc Natl Acad Sci U S A. 2011 Nov 22; 108(47):19024-9.
    View on PubMed
  11. Chen M, Pratt CP, Zeeman ME, Schultz N, Taylor BS, O'Neill A, Castillo-Martin M, Nowak DG, Naguib A, Grace DM, Murn J, Navin N, Atwal GS, Sander C, Gerald WL, Cordon-Cardo C, Newton AC, Carver BS, Trotman LC. Identification of PHLPP1 as a tumor suppressor reveals the role of feedback activation in PTEN-mutant prostate cancer progression. Cancer Cell. 2011 Aug 16; 20(2):173-86.
    View on PubMed
  12. Taylor BS, Barretina J, Maki RG, Antonescu CR, Singer S, Ladanyi M. Advances in sarcoma genomics and new therapeutic targets. Nat Rev Cancer. 2011 Aug; 11(8):541-57.
    View on PubMed
  13. Xing F, Persaud Y, Pratilas CA, Taylor BS, Janakiraman M, She QB, Gallardo H, Liu C, Merghoub T, Hefter B, Dolgalev I, Viale A, Heguy A, De Stanchina E, Cobrinik D, Bollag G, Wolchok J, Houghton A, Solit DB. Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring (V600E)BRAF. Oncogene. 2012 Jan 26; 31(4):446-57.
    View on PubMed
  14. Integrated genomic analyses of ovarian carcinoma. Nature. 2011 Jun 30; 474(7353):609-15.
    View on PubMed
  15. Ugras S, Brill E, Jacobsen A, Hafner M, Socci ND, Decarolis PL, Khanin R, O'Connor R, Mihailovic A, Taylor BS, Sheridan R, Gimble JM, Viale A, Crago A, Antonescu CR, Sander C, Tuschl T, Singer S. Small RNA sequencing and functional characterization reveals MicroRNA-143 tumor suppressor activity in liposarcoma. Cancer Res. 2011 Sep 1; 71(17):5659-69.
    View on PubMed
  16. Bott M, Brevet M, Taylor BS, Shimizu S, Ito T, Wang L, Creaney J, Lake RA, Zakowski MF, Reva B, Sander C, Delsite R, Powell S, Zhou Q, Shen R, Olshen A, Rusch V, Ladanyi M. The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat Genet. 2011 Jul; 43(7):668-72.
    View on PubMed
  17. Clegg NJ, Couto SS, Wongvipat J, Hieronymus H, Carver BS, Taylor BS, Ellwood-Yen K, Gerald WL, Sander C, Sawyers CL. MYC cooperates with AKT in prostate tumorigenesis and alters sensitivity to mTOR inhibitors. PLoS One. 2011; 6(3):e17449.
    View on PubMed
  18. Taylor BS, Ladanyi M. Clinical cancer genomics: how soon is now? J Pathol. 2011 Jan; 223(2):318-26.
    View on PubMed
  19. Brill E, Gobble R, Angeles C, Lagos-Quintana M, Crago A, Laxa B, Decarolis P, Zhang L, Antonescu C, Socci ND, Taylor BS, Sander C, Koff A, Singer S. ZIC1 overexpression is oncogenic in liposarcoma. Cancer Res. 2010 Sep 1; 70(17):6891-901.
    View on PubMed
  20. Joseph EW, Pratilas CA, Poulikakos PI, Tadi M, Wang W, Taylor BS, Halilovic E, Persaud Y, Xing F, Viale A, Tsai J, Chapman PB, Bollag G, Solit DB, Rosen N. The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. Proc Natl Acad Sci U S A. 2010 Aug 17; 107(33):14903-8.
    View on PubMed

Go to UCSF Profiles, powered by CTSI